This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF) severity categories based on the America...
We've found 8 total result s for "Cardiomyopathies".
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
Age: 12 - 17 years
Gender: All
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
Age: 18 - 85 years
Gender: All
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine p...
Age: 18 years - 66+
Gender: Female
The purpose of this study is to collect long-term safety and tolerability data for aficamten.
Age: 18 - 85 years
Gender: All
This is a prospective multi-center international registry. The objective of this registry is to collect prospective data on patients undergoing catheter ablation for Ventricular Tachycardia (VT) and Premature Ventricular Contractions (PVC). The registry will be used...
- Cardiomyopathies
- Arrhythmias, Cardiac
- Tachycardia
- Tachycardia, Ventricular
- Ventricular Premature Complexes
Age: Birth - 66+
Gender: All
This is a prospective multi-center international registry. The objective of this registry is to collect prospective data on patients undergoing catheter ablation for Ventricular Tachycardia (VT) and Premature Ventricular Contractions (PVC). The registry will be used ...
- Cardiomyopathies
- Arrhythmias, Cardiac
- Tachycardia
- Tachycardia, Ventricular
- Ventricular Premature Complexes
Age: Birth - 66+
Gender: All
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Age: 18 years - 66+
Gender: All